Institute of Parasitology and Biomedicine Lo´pez-Neyra, Consejo Superior de Investigaciones Científicas, Avda del Conocimiento s/n, 18100 Granada, Spain.
Hum Mol Genet. 2012 Feb 1;21(3):511-25. doi: 10.1093/hmg/ddr481. Epub 2011 Oct 19.
Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause late-onset Parkinson's disease, but its physiological function has remained largely unknown. Here we report that LRRK2 activates a calcium-dependent protein kinase kinase-β (CaMKK-β)/adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway which is followed by a persistent increase in autophagosome formation. Simultaneously, LRKR2 overexpression increases the levels of the autophagy receptor p62 in a protein synthesis-dependent manner, and decreases the number of acidic lysosomes. The LRRK2-mediated effects result in increased sensitivity of cells to stressors associated with abnormal protein degradation. These effects can be mimicked by the lysosomal Ca(2+)-mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) and can be reverted by an NAADP receptor antagonist or expression of dominant-negative receptor constructs. Collectively, our data indicate a molecular mechanism for LRRK2 deregulation of autophagy and reveal previously unidentified therapeutic targets.
LRRK2 基因突变导致晚发性帕金森病,但它的生理功能在很大程度上仍然未知。在这里,我们报告 LRRK2 激活钙依赖性蛋白激酶激酶-β(CaMKK-β)/腺苷单磷酸(AMP)激活蛋白激酶(AMPK)途径,随后持续增加自噬体的形成。同时,LRKR2 过表达以蛋白合成依赖的方式增加自噬受体 p62 的水平,并减少酸性溶酶体的数量。LRRK2 介导的作用导致细胞对与异常蛋白降解相关的应激原的敏感性增加。这些作用可以被溶酶体 Ca(2+)-动员信使烟酰胺腺嘌呤二核苷酸磷酸(NAADP)模拟,并且可以通过 NAADP 受体拮抗剂或显性负受体构建体的表达来逆转。总的来说,我们的数据表明了 LRRK2 对自噬的调控的分子机制,并揭示了以前未被识别的治疗靶点。